Dermatology

LED BLU-U, used in combination with LEVULAN KERASTICK, is capable of treating minimally to moderately thick actinic keratoses.

At 2025 New Wave Dermatology, HCPLive spoke with Miranti on treating the 4 pillars of pathogenesis, including sebum production, inflammation, and more.

At 2025 New Wave Dermatology, Zirwas highlights the most useful dermatology studies from the past 2 years, covering AD misdiagnosis, alopecia, contact dermatitis, and more.

Zirwas shares top dermatology studies, highlights AD misdiagnosis, and reveals how pollution and fabrics may trigger adult-onset atopic dermatitis.

Zirwas outlines a 4-visit approach to diagnosing spongiotic dermatitis, helping dermatologists manage uncertain rashes more effectively.

In this interview, Mona Shahriari, MD, and Raj Chovatiya, MD, PhD, touched on the evolving role of pharmacists and internal medicine doctors in atopic dermatitis.

At New Wave Derm 2025, Kalil shared expert tips on evaluating and diagnosing scarring vs non-scarring hair loss using clinical tools.

Kalil discusses the latest advancements in hair loss treatments, including innovative therapies and ongoing research in dermatology for effective solutions.

This interview with Jennifer Soung, MD, highlights the implications of recent phase 3 findings on roflumilast foam 0.3% (Zoryve) for psoriasis of the scalp and body.

In this retrospective study, investigators highlight the effectiveness and safety of baricitinib and systemic corticosteroid addition for alopecia areata.

In this cross-sectional study, investigators looked at the relationship between neighborhood-level socioeconomic status and hidradenitis suppurativa.

In this analysis, investigators looked at the extent to which psoriasis severity correlates with patients’ risk of developing sleep disorders.

These findings highlight the potential for JAKi use in alopecia areata in terms of associated neuroimmune dysregulation and comorbidities.

This interview with Andrew Alexis, MD, MPH, highlights the unique clinical challenges of high-impact areas of psoriasis such as the scalp and hands.

This episode of the SOCS podcast features an in-depth discussion between Tiffany Mayo, MD, Steven Daveluy, MD, and patient advocate Jasmine Ivanna Espy.

This multinational, retrospective study highlights the effect of omalizumab on chronic urticaria among patients at multiple urticaria care centers.

Stay updated with the latest healthcare breakthroughs, including cholesterol treatments and innovative therapies for AMD and psoriasis, in this week's roundup.

These data from the ICONIC-TOTAL trial program highlight icotrokinra’s use as a selective IL-23 inhibitor and its effectiveness in skin clearance for psoriasis.

These findings support the conclusion that switching between adalimumab biosimilars largely maintains efficacy for patients with psoriasis.

Notable psychosocial and occupational burdens, as well as impairments to emotional well-being, were seen among caregivers of adolescents with alopecia.

In this interview, Raj Chovatiya, MD, PhD, describes roflumilast cream's success in addressing unmet needs for atopic dermatitis.

These phase 3 findings from the ARRECTOR trial, published in JAMA, demonstrate rapid and significant relief from plaque psoriasis with roflumilast foam use.

This analysis highlighted the cardiovascular safety of systemic psoriasis drugs using a prospective cohort trial design.

These post-hoc analysis findings align with POETYK PSO-4 regarding deucravacitinib’s effectiveness in patients with psoriasis.

AI enhances prediction, diagnosis, and treatment of allergic diseases including asthma, atopic dermatitis, and food allergies, offering personalized, efficient care.